Kiora Pharmaceuticals announced that it has been granted U.S. Patent No. 12,364,680 for KIO-104, covering its use in treating various ocular diseases such as ocular inflammation, uveitis, age-related macular degeneration, and complications from refractive surgery. The patent also includes protections for dosing schedules, necessary excipients, and other methods optimizing the treatment of ocular inflammatory diseases. This patent is expected to extend market exclusivity for KIO-104 into 2043. KIO-104 is a small molecule designed to treat inflammatory retinal diseases by inhibiting the mitochondrial enzyme DHODH, reducing T-cell replication and inflammation.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiora Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 259471) on July 22, 2025, and is solely responsible for the information contained therein.